A Phase 1 interventional study of NNC0487-0111 and Placebo (matched to NNC0487-0111) in Obesity, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-04-27.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.
Among the 24 studies testing zenagamtide in Obesity, this one is the 17th largest by planned enrollment, is one of 19 that started in 2026, is one of 9 in phase 1, reaches primary completion later than 1 of the 19 other live ones, and was the 9th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18+
Novo Nordisk A/S · Sites in Japan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 19 started in 2026.
This study's planned enrollment of 120 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 360 across the 24 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 24 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 89th largest by planned enrollment of the 166 interventional ones that give a count, is one of 47 that started in 2026, is one of 85 in phase 1, reaches primary completion later than 33 of the 65 other live ones, and was the 169th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing zenagamtide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to look at if/how much NNC0487-0111 affects food intake, appetite and metabolism in participants with obesity when compared to placebo. There are 2 study treatments in this study. Participants will inject the study treatment under the skin of your stomach once a week. Participants will get either NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants will get is decided by chance.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive 1 of the different dose levels of NNC0487-0111 subcutaneously once weekly.
Drug: NNC0487-0111
Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly.
Drug: Placebo (matched to NNC0487-0111)
NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors into a skin fold on the abdomen.
Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors into a skin fold on the abdomen.
Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126
Measured as percentage change of energy.
Time frame: From Baseline to Day 126
Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 182
Measured as percentage change of energy.
Time frame: From Baseline to Day 182
Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 238
Measured as percentage change of energy.
Time frame: From Baseline to Day 238
Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126
Measured as kilojoules (kJ).
Time frame: From Baseline to Day 126
Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 182
Measured as kJ.
Time frame: From Baseline to Day 182
Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 238
Measured as kJ.
Time frame: From Baseline to Day 238
Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 126
Measured as grams.
Time frame: From Baseline to Day 126
Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 182
Measured as grams.
Time frame: From Baseline to Day 182
Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 238
Measured as grams.
Time frame: From Baseline to Day 238
Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 378
Measured as percentage change of energy.
Time frame: From Baseline to Day 378
Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box at Day 378
Measured as kJ.
Time frame: From Baseline to Day 378
Change from baseline in total amount of food consumed during ad libitum breakfast, lunch, evening meal and snack box to Day 378
Measured as grams.
Time frame: From Baseline to Day 378
Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 126
Measured as kJ.
Time frame: From Baseline to Day 126
Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 182
Measured as kJ.
Time frame: From Baseline to Day 182
Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 238
Measured as kJ.
Time frame: From Baseline to Day 238
Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 378
Measured as kJ.
Time frame: From Baseline to Day 378
Relative change from Day 19 in body weight to Day 131
Measured as percentage change of body weight.
Time frame: From Day 19 to Day 131
Relative change from Day 19 in body weight to Day 187
Measured as percentage change of body weight.
Time frame: From Day 19 to Day 187
Relative change from Day 19 in body weight to Day 243
Measured as percentage change of body weight.
Time frame: From Day 19 to Day 243
Relative change from Day 19 in body weight to Day 383
Measured as percentage change of body weight.
Time frame: From Day 19 to Day 383
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 21 months is above that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zenagamtide